Biomarker Testing for Personalized Therapy in Lung Cancer in Low- and Middle-Income Countries.

Specific PHGKB|Cancer|PHGKB

Lung Cancer Genomics

- Cancer PHGKB -

What's New

Last Posted: Dec 21, 2017

---

• Biomarker Testing for Personalized Therapy in Lung Cancer in Low- and Middle-Income Countries.  
  Hirsch Fred R et al. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting 2017 37403-408
• [THE IMPACT OF MOLECULAR PROFILING USING NEXT-GENERATION SEQUENCING IN ADVANCED LUNG CANCER].  
  Belilovski Rozenblum Anna et al. Harefuah 2017 Nov 156(11) 686-691
• Cell free DNA analysis by SiRe® next generation sequencing panel in non small cell lung cancer patients: focus on basal setting.  
  Pisapia Pasquale et al. Journal of thoracic disease 2017 Oct 9(Suppl 13) S1383-S1390
• Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.  
  Osmani Lais et al. Seminars in cancer biology 2017 Nov
• Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project.  
  Kerr K M et al. Annals of oncology : official journal of the European Society for Medical Oncology 2017 Nov
• Urine test for EGFR analysis in patients with non-small cell lung cancer.  
  Franovic Aleksandra et al. Journal of thoracic disease 2017 Oct 9(Suppl 13) S1323-S1331
• Additional Recommendations for ALK Gene-Rearranged Non-Small-Cell Lung Cancer to the Recently Updated American Society of Clinical Oncology Guideline for Stage IV Non-Small-Cell Lung Cancer.  
  Van Hoef Marlies E H M et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Nov JCO2017758367
• Identification of lung adenocarcinoma specific dysregulated genes with diagnostic and prognostic value across 27 TCGA cancer types.  
  Shang Jun et al. Oncotarget 2017 Oct 8(50) 87292-87306
• Surviving With Smog and Smoke: Precision Interventions?  
  Cai Hua et al. Chest 2017 Nov 152(5) 925-929
• A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.  
  Goldstein Daniel A et al. Journal of the National Cancer Institute 2017 Nov 109(11)